Assignment history

Inventors

• David Townley (Neurent Medical Ltd)

No unusual patterns observed regarding inventor departures.

Original assignee

Neurent Medical Ltd. is the current assignee.
Neurent Medical Ltd. develops medical devices for the treatment of chronic inflammatory nasal diseases. Their primary line of business is therapeutic neuromodulation for nasal treatment. They appear to be an operating company, actively developing and shipping products embodying the claims, specifically, their "NEUROMARK System" for treating chronic rhinitis.
Current Status: Operating.

Assignment timeline

• 2024-01-12 (filed) / recorded 2024-04-11 — Reel 059952/0038

  • Conveyance: Assignment
  • Assignor: TOWNLEY, David
  • Assignee: Neurent Medical Limited
  • Correspondent: GERRY J. WEISS, HOUSTON, TX, US.
  • Context: Inventor to operating company assignment.

• 2024-10-18 (executed) / recorded 2024-10-18 — Reel 061633/0843

  • Conveyance: Security Interest
  • Assignor: Neurent Medical Limited
  • Assignee: CLARET EUROPEAN SPECIALTY LENDING COMPANY III, S.A R.L.
  • Correspondent: BRIAN LEACH, DLA Piper LLP (US), Austin, TX, US.
  • Context: Securitization.

Timeline diagram

timeline
    title Ownership of US 11998262
    2020 : Priority date
    2024 : Filed by Neurent Medical Ltd
         : Inventor assigned to Neurent Medical Ltd
         : Security interest granted to Claret European Specialty Lending Company III SARL
    2024 : Issued

NPE / troll-pattern signals

1. Shell-entity transfer — not present. The initial assignment is from the inventor to an operating company (Neurent Medical Ltd.). The subsequent record is a security interest, not a transfer of ownership, to a lending company.
2. Known asserter in the chain — not present. Neurent Medical Ltd. is an operating company, and CLARET EUROPEAN SPECIALTY LENDING COMPANY III, S.A R.L. is a lending institution, neither of which are known NPEs.
3. Repeat correspondent across the chain — not present. The correspondent for the assignment is GERRY J. WEISS, and the correspondent for the security interest is BRIAN LEACH, DLA Piper LLP (US). These are different.
4. Cascading transfers — not present. There is only one transfer of ownership (from inventor to the operating company) and one security interest, not multiple consecutive transfers through chained LLCs.
5. Pre-litigation transfer — not present. The patent was granted on June 4, 2024. The only ownership assignment record is from the inventor to Neurent Medical Ltd. on April 11, 2024, which is before issuance. The other record is a security interest dated October 18, 2024, after issuance. There is no indication of litigation immediately following these events.
6. Bankruptcy fire-sale — not present. There is no indication that Neurent Medical Ltd. has filed for bankruptcy.
7. Privateering — unclear. There is no public information in the patent record or Google Patents legal events to suggest privateering.
8. Defensive aggregator (anti-NPE) — not present. The current assignee is Neurent Medical Ltd., an operating company, and there are no records indicating transfer to a defensive aggregator.

Verdict

Operating-company assertion (current assignee ships products embodying the claims and is suing actual competitors)

The patent is currently assigned to Neurent Medical Ltd., an operating company that develops and markets medical devices for nasal treatment. The only other recorded event is a security interest with a lending institution, which is a common operating-company financing activity. There are no signals of shell entities, known asserters, or other NPE patterns.

For verification, refer to the USPTO Assignment Center search page: https://assignmentcenter.uspto.gov/